The NCI Myeloma Steering Committee (MYSC) was established in 2009. At monthly meetings, it addresses the design, prioritization, and evaluation of concepts for phase II and phase III clinical trials in adult myeloma. View the MYSC member roster as of November 7, 2025. The committee may periodically hold clinical trials planning meetings (CTPMs) to focus on specific clinical trial related topics.
Committee Highlights
The following are highlights from recent committee activities:
- Strategies and Planning Working Group
The MYSC convened a meeting in May 2011 to develop a working definition for high risk myeloma and share ideas for clinical trials, translational studies, and accrual issues for myeloma patients. Read the executive summary.
Contact
For more information, contact NCI CCCT Program Director, Elena Schwartz, Ph.D., M.S., at elena.schwartz@nih.gov.